✦ LIBER ✦

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

✍ Scribed by Ho-Young Yhim; Na-Ri Lee; Eun-Kee Song; Chang-Yeol Yim; So Yeon Jeon; Seunghwan Shin; Jeong-A Kim; Hee Sun Kim; Eun Hae Cho; Jae-Yong Kwak

Book ID: 113773681
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 270 KB
Volume: 36
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2012.02.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sustained complete cytogenetic remission

Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy

✍ Seiichi Okabe; Tetsuzo Tauchi; Yuko Ishii; Daigo Akahane; Kousuke Nunoda; Seiko 📂 Article 📅 2007 🏛 Carden Jennings Publishing 🌐 English ⚖ 45 KB

Durable responses in chronic myeloid leu

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

✍ Angelo Michele Carella; Enrica Lerma 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 88 KB

Phase 1 study of lonafarnib (SCH 66336)

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

✍ Jorge Cortes; Elias Jabbour; George Q. Daley; Susan O'Brien; Srdan Verstovsek; A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

## Abstract ## BACKGROUND. Lonafarnib is an orally bioavailable nonpetidomimetic farnesyl transferase inhibitor with significant activity against BCR‐ABL‐positive cell lines and primary human chronic myeloid leukemia (CML) cells. Lonafarnib can inhibit the proliferation of imatinib‐resistant cells

Imatinib mesylate therapy in chronic mye

Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate

✍ Giuliana Alimena; Massimo Breccia; Luigia Luciano; Fabrizio Quarantelli; Daniela 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 205 KB

To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic myeloid leukaemia (CP-CML) patients responsive to interferon-alpha (IFNalpha), in stable complete cytogenetic response (CCR) but with persistent PCR positivity. Twenty-six Philadelphia positive (Ph+) C

Emergence of Ph negative clones in chron

Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI)

✍ Alessandro Gozzetti; Daniela Tozzuoli; Rosaria Crupi; Sara Gentili; Monica Bocch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Chronic myelogenous leukemia in T cell l

Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy

✍ Ehab Atallah; Moshe Talpaz; Susan O'brien; Mary Beth Rios; Jie Qiang Guo; Ralph 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

## Abstract ## BACKGROUND A T cell lymphoid blastic phase of chronic myelogenous leukemia (CML) is a rare occurrence, with only a few reported cases worldwide. Standard therapy for such patients is undetermined. Imatinib mesylate, a Bcr‐Abl tyrosine kinase inhibitor, has shown activity in CML. ##